Logo image of RVX.CA

RESVERLOGIX CORP (RVX.CA) Stock Fundamental Analysis

TSX:RVX - Toronto Stock Exchange - CA76128M1086 - Common Stock - Currency: CAD

0.05  0 (0%)

Fundamental Rating

0

RVX gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 25 industry peers in the Biotechnology industry. RVX may be in some trouble as it scores bad on both profitability and health. RVX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year RVX has reported negative net income.
RVX had a negative operating cash flow in the past year.
RVX had negative earnings in 4 of the past 5 years.
RVX had a negative operating cash flow in each of the past 5 years.
RVX.CA Yearly Net Income VS EBIT VS OCF VS FCFRVX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -145.66%, RVX is in line with its industry, outperforming 47.62% of the companies in the same industry.
Industry RankSector Rank
ROA -145.66%
ROE N/A
ROIC N/A
ROA(3y)-183.15%
ROA(5y)-102.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RVX.CA Yearly ROA, ROE, ROICRVX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RVX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RVX.CA Yearly Profit, Operating, Gross MarginsRVX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

0

2. Health

2.1 Basic Checks

The number of shares outstanding for RVX has been increased compared to 1 year ago.
RVX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for RVX is higher compared to a year ago.
RVX.CA Yearly Shares OutstandingRVX.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M
RVX.CA Yearly Total Debt VS Total AssetsRVX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -90.81, we must say that RVX is in the distress zone and has some risk of bankruptcy.
RVX's Altman-Z score of -90.81 is on the low side compared to the rest of the industry. RVX is outperformed by 71.43% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -90.81
ROIC/WACCN/A
WACCN/A
RVX.CA Yearly LT Debt VS Equity VS FCFRVX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M -60M

2.3 Liquidity

A Current Ratio of 0.08 indicates that RVX may have some problems paying its short term obligations.
RVX has a worse Current ratio (0.08) than 85.71% of its industry peers.
RVX has a Quick Ratio of 0.08. This is a bad value and indicates that RVX is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of RVX (0.04) is worse than 95.24% of its industry peers.
Industry RankSector Rank
Current Ratio 0.08
Quick Ratio 0.04
RVX.CA Yearly Current Assets VS Current LiabilitesRVX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

0

3. Growth

3.1 Past

RVX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.72%, which is quite good.
EPS 1Y (TTM)14.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RVX.CA Yearly Revenue VS EstimatesRVX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
RVX.CA Yearly EPS VS EstimatesRVX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -0.1 -0.2 -0.3 -0.4

0

4. Valuation

4.1 Price/Earnings Ratio

RVX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RVX.CA Price Earnings VS Forward Price EarningsRVX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RVX.CA Per share dataRVX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

RVX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

RESVERLOGIX CORP

TSX:RVX (2/13/2025, 7:00:00 PM)

0.05

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07
Earnings (Next)03-28 2025-03-28
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners0.57%
Ins Owner ChangeN/A
Market Cap14.03M
Analysts80
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.06
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0
BVpS-0.42
TBVpS-0.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -145.66%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-183.15%
ROA(5y)-102.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 111.84%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.08
Quick Ratio 0.04
Altman-Z -90.81
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)62.13%
Cap/Depr(5y)81.43%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-39.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-47.19%
OCF growth 3YN/A
OCF growth 5YN/A